Clozapine-associated diabetes

American Journal of Medicine

Volumn 111, Issue 9, 2001, Pages 716-723

  Koller, Elizabeth ^a   Schneider, Bruce ^a   Bennett, Katherine ^a   Dubitsky, Greg ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; GLUCOSE INTOLERANCE; HUMAN; HYPERGLYCEMIA; HYPEROSMOLAR COMA; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MORTALITY; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE DISTRIBUTION; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS;

EID: 0035893949     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(01)01000-2     Document Type: Article

References (59)

1. Medical complications of new antipsychotic drugs
2. Diabetic ketoacidosis and clozapine
3. Clozapine-induced diabetic ketoacidosis: Report of a case and critical review of the literature
4. Diabetes mellitus after treatment with clozapine
5. Diabetic ketoacidosis associated with clozapine treatment
6. Lethal interaction of clozapine and buspirone?
7. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
8. Insulin-resistant hyperglycemia induced by clozapine
9. Severe hyperglycemia associated with high doses of clozapine
10. Clozapine-associated diabetes
11. Ketoacidosis as a side effect of clozapine: A case report
12. Lactic acidosis and fatal myocardial infarction due to clozapine
13. Diabetic ketoacidosis with clozapine treatment
14. Diabetic ketoacidosis with clozapine treatment
15. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses
16. Schizophrenia and diabetes mellitus
17. Diabetic ketoacidosis from clozapine and lithium cotreatment
18. Clozapine monotherapy and ketoacidosis
19. Clozapine and associated diabetes mellitus
20. Diabetes mellitus after treatment with clozapine
21. Diabetes as the result of anti-psychotic drugs: A report of three cases
22. Clozapine-induced diabetic ketoacidosis
23. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria, and proteinuria occurring early in clozapine treatment
24. Diabetes mellitus associated with clozapine therapy
25. Novel antipsychotics and new onset diabetes
26. Hyperglycemia, hyperlipidemia, and periodic paralysis: A case report of new side effects of clozapine
27. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
28. Prevalence and incidence of non-insulin dependent diabetes
29. Schizophrenia and other psychotic disorders
30. Incidence of adverse drug events and potential adverse drug events: Implications for prevention
31. Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse events
32. Attitudinal survey of voluntary reporting of adverse drug reactions
33. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age
34. Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: Risk and predictors of under-reporting
35. Reporting of adverse drug reactions by hospital doctors and the response to intervention
36. Physician knowledge, attitudes, and behavior related to reporting adverse drug events
37. Hospital pharmacy compliance with JCAHO standards and ASHP guidelines for reporting adverse drug reactions
38. Clozapine and body mass change
39. Effect of chlorpromazine (CPZ) on insulin release in vivo and in vitro in the rat
40. Neuroleptic malignancy syndrome and diabetic keto-acidosis
41. Hyperglycemia associated with olanzapine
42. Diabetic ketoacidosis with olanzapine treatment
43. New-onset diabetes mellitus, and diabetic ketoacidosis associated with olanzapine treatment
44. Hyperglycemia and olanzapine
45. Olanzapine-induced ketoacidosis with diabetes
46. Hyperglycemia and ketoacidosis associated with olanzapine
47. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics
48. Relationship between patient variables and plasma clozapine concentrations: A dosing nomogram
49. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses
50. Glucose-insulin metabolism in chronic schizophrenia
51. Prevalence and correlates of diabetes in national schizophrenia samples
52. The reciprocally modifying effects of schizophrenia and diabetes mellitus on their phenotypic manifestations
53. Diabetes and schizophrenia
54. Diabetes mellitus in schizophrenic patients
55. Autoimmune diseases in the pedigrees of schizophrenic and control subjects
56. Persistent tardive dyskinesia and neuroleptic effects on glucose tolerance
57. Impaired glucose tolerance and abnormal movements in patients with schizophrenia